Sciton Women’s Health Group Announces Presentation of diVa® Hybrid Laser Pilot Study Clinical Data at International Urogynecological Association 42nd 2017 Annual Meeting
PALO ALTO, Calif., June 19, 2017 /PRNewswire/ – Sciton, Inc. Women’s Health Group today announced interim and final results of a pilot study of its novel diVa Hybrid Laser for the treatment of GSM (Genitourinary Symptoms of Menopause). The abstract will be presented in a podium presentation at the International Urogynecological Association (IUGA) 2017 Annual Meeting, which will take place June 20-24 in Vancouver, Canada by Nathan Guerette MD, FACOG, FAAFP, FPMRS who was the Clinical Investigator conducting the pilot study.
The abstract, is titled “Novel Hybrid Fractional Erbium-YAG Laser (diVa®, Sciton Inc., CA, USA) for the Treatment of GSM”. Abstract selection is a rigorous process based on merit, scientific relevance, and contribution to clinical outcomes. The presentation will provide details and values of data addressing symptoms in 24 subjects, aged 26-72. Included for discussion is comfortability and ease of post procedure effects for the series of 3 treatments. The data stats were verified with Wilcoxon ranked testing. The study supports the objective of ministering real solutions to women’s intimate health issues. The abstract presentation will be on Saturday, June 24th at 12pm (PDT).
GSM is associated with decrease in estrogen in women. As the female population ages and expectations increase, the symptoms have become epidemic. Estimates range in 50% of women who have reached menopause. Vaginal estrogen supplementation has been the cornerstone to treat these symptoms. Estrogen, however, has risk, is not always successful, and not an option for many women with hormone driven pathology such as breast cancer. Recently, energy-based treatments for GSM have become more common and initial data is promising. Initial intra-vaginal energy-based technology is limited and does not vary treatment depths or the density of tissue treated, thus limiting the success of the treatment and variety of symptoms treatable. The study results are evaluated and summarized of data collected from use of a novel, hybrid, fractional, automated, Erbium-YAG laser (diVa) for its unique “tunable” ability for customization of varying depths and density.
ABOUT DR. NATHAN GUERETTE
Dr. Nathan Guerette is internationally recognized in his field and has presented and published over 100 topics both at a national and international level and has contributed significant original research to the practice of Urogynecology and Pelvic Reconstructive Surgery. He currently serves as Director and CEO of The Female Pelvic Medicine Institute of Virginia™. As a world renowned Urogynecologist, he performs over 600 reconstructive pelvic surgeries a year and is the most experienced robotic female pelvic reconstructive surgeon in the region. The Female Pelvic Medicine Institute actively participates in clinical research to advance care for women including many FDA level studies. He holds a key position on the Sciton Clinical Review Board.
ABOUT THE diVa SYSTEM
diVa expands the broad range of Sciton’s JOULE™ platform capabilities to address a woman’s most intimate challenges. diVa is the world’s first hybrid fractional laser for Vaginal Therapy and Vaginal Restoration. diVa is the only device available that includes HPA (High Precision Automation) technology to enhance predictability for the operator. Additionally, diVa’s dual-wavelength hybrid technology and tunability allows operators to customize treatments based on a patient’s age, symptoms, and desired results.
Sciton, Inc., located in Palo Alto, California, is a totally employee-owned company, medical device company established in 1997 by co-founders James Hobart, Ph.D., and Daniel Negus, Ph.D. Sciton was established with a focus on long-term results and making both patients and physicians happy. Sciton offers superior medical devices to treat women’s health conditions, vascular lesions, pigmentation, skin texture and tone, scars, body contouring, skin laxity and hair reduction. Sciton operates on a worldwide basis with direct sales forces in the United States, Canada, Japan, Australia and distributor partners in more than 45 countries. For more information, and a complete listing of Sciton systems, visit www.sciton.com
Sciton’s innovation, from Erbium lasers to dual flash-lamp technology, helped to improve concerns of existing treatments by increasing efficiency, minimizing downtime, and enhancing patient results.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sciton-womens-health-group-announces-presentation-of-diva-hybrid-laser-pilot-study-clinical-data-at-international-urogynecological-association-42nd-2017-annual-meeting-300473819.html
SOURCE Sciton, Inc.